What changed
$WST — ADD 📊
West Pharmaceutical Services, Inc.
🎯 Q1 FY26 | Rev $1B | EPS $2.13 vs $1.68 🟢
💡 Consensus expects ~$8.50 EPS in FY26, but we believe WST can deliver $9.00+ as biosimilar demand accelerates and operating leverage improves. The market views the stock as fully valued at 38x, but historical premium of 44x suggests room for multiple expansion as growth visibility increases.
📉 Reward/Risk: 2.3:1
🏢 Business Quality: 8/10 - Wide moat from proprietary elastomeric components and long-term contracts with pharma/biotech; essential role in drug delivery with high switching costs; strong cash flows, but capex and regulatory changes pose moderate risk.
📊 Valuation: fair - Forward P/E of 38x vs historical median 44.5x; EV/EBITDA likely mid-20s; DCF implies 7-8% FCF yield terminal growth; reference-class peers...
📊 Our read: ADD. Full analysis →
https://stockduty.xyz/s/WST0618
Also in play: $WAB $GBX $TRN $CAT $DE $NSC